Biomarker Rigor

A new collaborative between the US Food and Drug Administration, National Cancer Institute (NCI), and Centers for Medicare and Medicaid Services will bring scientific rigor and validation to biomarker research, say the agencies. The Oncology Biomarker Qualification Initiative (OBQI; www.fda.gov/oc/mous/domestic/FDA-NCI-CMS.html ) will be "a partnership between these three agencies to really for the first time collectively think about how we create the evidence base for biomarkers," says Anna Barker, deputy director of NCI.


	The article you are attempting to read is Premium content which is only available to our online subscribers.

Subscribing to The Scientist is easy and inexpensive.

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.


	The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study. Recommend The Scientist today